ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENGN ENGENE HOLDINGS INC

Not Yet Opened 04-22 16:00:00 EDT

8.54

+0.03

+0.35%

盘后8.37

-0.17-1.99%

18:09 EDT

High8.67	Low8.25	Vol340.55K
Open8.57	D1 Closing8.51	Amplitude4.94%
Mkt Cap572.05M	Tradable Cap318.82M	Total Shares66.98M
T/O2.89M	T/O Rate0.91%	Tradable Shares37.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ENGN","market":"US","secType":"STK","nameCN":"ENGENE HOLDINGS INC","latestPrice":8.54,"timestamp":1776888000000,"preClose":8.51,"halted":0,"volume":340553,"hourTrading":{"tag":"盘后","latestPrice":8.37,"preClose":8.54,"latestTime":"18:09 EDT","volume":1266,"amount":10718.56,"timestamp":1776895751351,"change":-0.17,"changeRate":-0.019906,"amplitude":0.019906},"delay":0,"changeRate":0.0035252643948295373,"floatShares":37332800,"shares":66984661,"eps":-2.2529,"marketStatus":"Not Yet Opened","change":0.03,"latestTime":"04-22 16:00:00 EDT","open":8.57,"high":8.67,"low":8.25,"amount":2893811.075,"amplitude":0.049354,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.2529,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776931200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":8.51,"postHourTrading":{"tag":"盘后","latestPrice":8.37,"preClose":8.54,"latestTime":"18:09 EDT","volume":1266,"amount":10718.56,"timestamp":1776895751351,"change":-0.17,"changeRate":-0.019906,"amplitude":0.019906},"volumeRatio":0.891963,"impliedVol":0.3939,"impliedVolPercentile":0.3077},"requestUrl":"/m/hq/s/ENGN","defaultTab":"news","newsList":[{"id":"2627457081","title":"enGene Holdings Initiated at Buy by WBB Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2627457081","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627457081?lang=en_us&edition=fundamental","pubTime":"2026-04-14 01:25","pubTimestamp":1776101100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 13:25 ET (17:25 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626513086","title":"enGene Holdings changes name to enGene Therapeutics as it eyes 2027 launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2626513086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626513086?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:03","pubTimestamp":1775765010,"startTime":"0","endTime":"0","summary":"enGene Holdings will rebrand as enGene Therapeutics, signaling a shift toward a potential commercial-stage profile tied to anticipated 2027 approval of lead program detalimogene voraplasmid.Pipeline timeline calls for a biologics license application submission for detalimogene in 2H 2026.Nasdaq tickers remain ENGN for common shares and ENGNW for warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLbXWPVt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625309419","title":"BRIEF-Engene Holdings Inc - To Change Name To Engene Therapeutics Inc. Effective April 8, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625309419","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625309419?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:04","pubTimestamp":1775563463,"startTime":"0","endTime":"0","summary":"BRIEF-Engene Holdings Inc - To Change Name To Engene Therapeutics Inc. Effective April 8, 2026April 7 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE HOLDINGS INC - TO CHANGE NAME TO ENGENE THERAPEUTICS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q01Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","ENGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625793063","title":"enGene Holdings Inc - Planned Bla Submission for Detalimogene in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625793063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625793063?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:01","pubTimestamp":1775563294,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q01Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","ENGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625293056","title":"enGene Holdings Inc - to Change Name to enGene Therapeutics Inc. Effective April 8, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625293056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625293056?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:01","pubTimestamp":1775563294,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q01Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930308","title":"enGene Holdings changes name to enGene Therapeutics effective April 8, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930308","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930308?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:00","pubTimestamp":1775563243,"startTime":"0","endTime":"0","summary":"enGene Holdings will rebrand as enGene Therapeutics, signaling a shift toward a commercial-stage profile ahead of a potential 2027 approval for lead bladder cancer candidate detalimogene voraplasmid.Shares will continue to trade on Nasdaq under ticker ENGN; warrants will remain listed under ENGNW.LEGEND trial remains focused on high-risk non-muscle invasive bladder cancer, including a pivotal cohort in BCG-unresponsive disease with carcinoma in situ.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire  on April 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL8m4HQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625267191","title":"Three new option listings and three option delistings on April 6th","url":"https://stock-news.laohu8.com/highlight/detail?id=2625267191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625267191?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:30","pubTimestamp":1775478637,"startTime":"0","endTime":"0","summary":"New option listings for April 6th include enGene Holdings Inc (ENGN), Keel Infrastructure Corp. (KEEL), and NovaBay Pharmaceuticals Inc (SDEV). Opt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/three-new-option-listings-and-three-option-delistings-on-april-6th-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/three-new-option-listings-and-three-option-delistings-on-april-6th-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENGN","KEEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621107937","title":"enGene price target lowered to $9 from $10 at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2621107937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621107937?lang=en_us&edition=fundamental","pubTime":"2026-03-22 22:50","pubTimestamp":1774191006,"startTime":"0","endTime":"0","summary":"UBS analyst David Dai lowered the firm’s price target on enGene (ENGN) to $9 from $10 and keeps a Neutral rating on the shares following the fiscal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-price-target-lowered-to-9-from-10-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-price-target-lowered-to-9-from-10-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LU1863844749.USD","IE0034235071.USD","ENGN","LU1829250122.USD","UBS","BK4534","LU1863844665.USD","BK4139","LU3187612489.SGD","BK4118"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621710681","title":"Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Boston Scientific (BSX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621710681","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621710681?lang=en_us&edition=fundamental","pubTime":"2026-03-22 22:00","pubTimestamp":1774188041,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on enGene Holdings (ENGN) and Boston Scientific (BSX). enGene Holdin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-engene-holdings-engn-and-boston-scientific-bsx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-engene-holdings-engn-and-boston-scientific-bsx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0238689110.USD","LU0011850046.USD","LU1720051017.SGD","LU0077335932.USD","BK4581","LU0187121727.USD","IE0009355771.USD","LU0823417653.USD","LU0122379950.USD","LU2506952170.USD","LU0345769128.USD","LU1791710400.SGD","LU0029874061.USD","LU0251132253.USD","LU1057294990.SGD","LU2265009873.SGD","XBI","LU0353189763.USD","LU0950375773.USD","LU1720051108.HKD","LU2242649171.HKD","IE00B4R5TH58.HKD","BK4137","BSX","LU0345769631.USD","LU0823417737.USD","IE00BJT1NW94.SGD","LU1989772840.SGD","LU2491049909.HKD","LU2357305700.SGD","SG9999001176.USD","LU0267386448.USD","LU0823416689.USD","LU1804176565.USD","LU1153585028.USD","LU2506952097.USD","XLV","LABU","LU2491050154.USD","LU0882574055.USD","LU2506951958.HKD","HCSG","IE00BJJMRZ35.SGD","LU0225283273.USD","LU1989772923.USD","IE00B2B36J28.USD","LU2506951875.HKD","LU2491050071.SGD","ENGN","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618928049","title":"enGene Holdings Inc. : Oppenheimer Cuts Target Price to $30 From $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618928049?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:57","pubTimestamp":1773237430,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nAZN4SKQ70:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618934617","title":"enGene Holdings (ENGN) Gets a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934617?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:58","pubTimestamp":1773140336,"startTime":"0","endTime":"0","summary":"In a report released today, Yanan Zhu from Wells Fargo maintained a Buy rating on enGene Holdings, with a price target of $25.00. Zhu covers the He...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/engene-holdings-engn-gets-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/engene-holdings-engn-gets-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0162691827.USD","LU0477156953.USD","BK4501","LU1363072403.SGD","ENGN","LU0742534661.SGD","LU0310800379.SGD","LU0106831901.USD","LU0267386448.USD","LU0310800965.SGD","BK4559","LU0149725797.USD","LU2236285917.USD","LU0942090050.USD","LU0208291251.USD","LU0289960550.SGD","LU0320765489.SGD","LU1267930227.SGD","BK4585","LU1894683264.USD","LU0640476718.USD","LU0310799852.SGD","LU0070302665.USD","LU0175139822.USD","LU2361045086.USD","LU0971096721.USD","IE0002270589.USD","LU0072461881.USD","LU2361044865.SGD","LU0048573561.USD","LU1894683348.USD","LU1267930573.SGD","LU0130517989.USD","LU0052756011.USD","LU0029864427.USD","LU1668664300.SGD","LU2361044949.HKD","LU0130102774.USD","LU0980610538.SGD","BK4139","IE00B19Z3B42.SGD","LU0787776722.HKD","LU0683600562.USD","LU1280957306.USD","LU0251142724.SGD","IE00B19Z3581.USD","LU0128525689.USD","LU1814569148.SGD","BK4588","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618998934","title":"enGene price target lowered to $27 from $30 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2618998934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618998934?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:56","pubTimestamp":1773140188,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Michael Schmidt lowered the firm’s price target on enGene (ENGN) to $27 from $30 and keeps a Buy rating on the shares after the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-price-target-lowered-to-27-from-30-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-price-target-lowered-to-27-from-30-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618783296","title":"enGene Holdings Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618783296","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618783296?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:03","pubTimestamp":1773072180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 12:03 ET (16:03 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618621635","title":"enGene Holdings Inc reports results for the quarter ended January 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621635","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621635?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:31","pubTimestamp":1773063081,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc reports results for the quarter ended January 31 - Earnings SummaryenGene Holdings Inc ENGN.OQ reported a quarterly adjusted loss of 44 cents per share for the quarter ended Januar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL8N3ZX1BY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618281016","title":"BRIEF-Engene Holdings Enters Sales Agreement With Leerink Partners To Sell Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618281016","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618281016?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:25","pubTimestamp":1773055536,"startTime":"0","endTime":"0","summary":"BRIEF-Engene Holdings Enters Sales Agreement With Leerink Partners To Sell Common SharesMarch 9  - enGene Holdings Inc ENGN.O:ENGENE HOLDINGS INC - ENTERS SALES AGREEMENT WITH LEERINK PARTNERS TO SELL COMMON SHARES - SEC FILINGENGENE HOLDINGS INC - SALES AGREEMENT ALLOWS OFFERING OF COMMON SHARES UP TO $100 MILLION - SEC FILINGFurther company coverage: ENGN.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618582628","title":"enGene Holdings Q1 EPS $(0.44) Beats $(0.58) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618582628","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618582628?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:18","pubTimestamp":1773055106,"startTime":"0","endTime":"0","summary":"enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.58) by 24.53 percent. This is a 8.33 percent increase over losses of $(0.48) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51122936/engene-holdings-q1-eps-0-44-beats-0-58-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618628320","title":"enGene Holdings Inc - Enters Sales Agreement With Leerink Partners to Sell Common Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628320?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:16","pubTimestamp":1773054986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640489","title":"enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640489?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:01","pubTimestamp":1773054064,"startTime":"0","endTime":"0","summary":"enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million. enGene reported a Q1 net loss attributable to common shareholders of USD 29.75 million, or USD 0.44 per share. Total operating expenses rose 17% to USD 31.19 million, including R&D expenses up 11% to USD 22.26 million. General and administrative expenses increased 35% to USD 8.93 million. Cash, cash equivalents and marketable securities totaled USD 312.55 million as of Jan. 31, and enGene said it expects this to fund operations into the second half of 2028. Management said a LEGEND pivotal cohort update is planned for a spring 2026 medical conference, with a BLA submission for detalimogene planned for the second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL8M6MDf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640024","title":"enGene Holdings Q1 Net Loss $0.44 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640024?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA7YTZXL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640488","title":"Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640488?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"LEGEND pivotal cohort update planned for a spring 2026 medical conference. 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026. Biologics License Application  submission for detalimogene planned for 2H 2026. Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028. enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update.\"As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,\" said Ron Cooper, President and Chief Executive Officer, enGene. \"On the heels of our successful November follow-on offering, we entered 2026 in a position of financial strength and ready to execute. With RMAT and CDRP designations for detalimogene, we are in active dialogue with the FDA to ensure regulatory ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971096721.USD","LU0267386448.USD","LU2746668974.SGD","BK4135","IE00BKVL7J92.USD","LU2237443465.HKD","CR","R","LU2746668461.USD","ENGN","BK4585","LU2237443895.HKD","LABU","BK4022","DDX","LU1363072403.SGD","LU2237443622.USD","BK4232","IE00B1BXHZ80.USD","LU0882574139.USD","CMC","LU2237443382.USD","LU0149725797.USD","LU0170899867.USD","TRAE","BK4006","IE00BHPRN162.USD","BK4139","HTGC","BCG","IE00BZ1G4Q59.USD","BK4161","IE00BFXG1179.USD","LU2237443978.SGD","LU2237443549.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.engene.com","stockEarnings":[{"period":"1week","weight":0.1005},{"period":"1month","weight":0.1683},{"period":"3month","weight":-0.1974},{"period":"6month","weight":0.0333},{"period":"1year","weight":1.135},{"period":"ytd","weight":-0.0543}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.0852},{"period":"3month","weight":0.0323},{"period":"6month","weight":0.0501},{"period":"1year","weight":0.3489},{"period":"ytd","weight":0.043}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.","exchange":"NASDAQ","name":"ENGENE HOLDINGS INC","nameEN":"ENGENE HOLDINGS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ENGENE HOLDINGS INC,ENGN,ENGENE HOLDINGS INC股票,ENGENE HOLDINGS INC股票老虎,ENGENE HOLDINGS INC股票老虎国际,ENGENE HOLDINGS INC行情,ENGENE HOLDINGS INC股票行情,ENGENE HOLDINGS INC股价,ENGENE HOLDINGS INC股市,ENGENE HOLDINGS INC股票价格,ENGENE HOLDINGS INC股票交易,ENGENE HOLDINGS INC股票购买,ENGENE HOLDINGS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}